Vandetanib is an oral, once-daily, small-molecule inhibitor of multiple tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET), primarily used in the treatment of symptomatic or progressive medullary thyroid cancer.